NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01506336,Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib,https://clinicaltrials.gov/study/NCT01506336,,COMPLETED,The objective is to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib.,NO,Gastro Intestinal Stromal Tumor,DRUG: masitinib|DRUG: sunitinib,"overall progression free survival, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 weeks, up to 36 weeks","overall survival, From date of randomization until the date of death from any cause, assessed up to 36 weeks, up to 36 weeks",,AB Science,,ALL,"ADULT, OLDER_ADULT",PHASE2,44,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,AB07001,2008-10,2011-09,2012-04,2012-01-10,,2018-12-11,"Institute Gustave Roussy (IGR), Villejuif, 94815, France",
